Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Goldfinch Bio
AddedFeb 13, 2024
UpdatedJun 18, 2026
Goldfinch Bio

Goldfinch Bio

Public

Goldfinch Biopharma, Inc.: A Massachusetts-based pharmaceutical company developing and manufacturing medicines.

HQ
Cambridge, MA, US
Founded
2015
Overview
Compare
Fundraising
Employees

Goldfinch Biopharma, Inc. is a Massachusetts-based pharmaceutical company focused on developing and manufacturing innovative medicines. Its core mission is to address unmet medical needs through advanced therapeutic solutions. The company serves a diverse market with a particular emphasis on creating treatments for kidney diseases.

Goldfinch Biopharma has made significant strides in the biotech industry, contributing to advancements in medical treatments. The company’s impactful work has garnered attention and support from key stakeholders in the healthcare sector.

Goldfinch Bio - Similar Companies

Kyntra Bio logo

Kyntra Bio

fibrogen.com

Apic Bio logo

Apic Bio

BridgeBio Pharma logo

BridgeBio Pharma

bridgebio.com

Boston Biopharma logo

Boston Biopharma

Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

kiniksa.com

Sinogen Biopharma logo

Sinogen Biopharma

Generation Bio logo

Generation Bio

generationbio.com

Walden Biosciences logo

Walden Biosciences

Geneicd logo

Geneicd

G2B Pharma logo

G2B Pharma

Brighton Biotech logo

Brighton Biotech

BiotechInnova logo

BiotechInnova

biotechinnova.com

NeuroFine logo

NeuroFine

Bionpharma logo

Bionpharma

bionpharma.com

Alphina Therapeutics logo

Alphina Therapeutics

Goldfinch Bio - Quick Facts

Who are Goldfinch Bio's competitors?

Companies similar to Goldfinch Bio include Kyntra Bio, Apic Bio, BridgeBio Pharma and Boston Biopharma.

When was Goldfinch Bio founded?

Goldfinch Bio was founded in 2015.

Where is Goldfinch Bio's headquarters located?

Goldfinch Bio's headquarters is located in Cambridge, MA, US.

When was Goldfinch Bio's last funding round?

Goldfinch Bio's most recent funding round was for $100M (USD) in June 2020.

How much has Goldfinch Bio raised to-date?

As of Jun 30, 2020, Goldfinch Bio has raised a total of $210M (USD).

How many employees does Goldfinch Bio have?

Goldfinch Bio has 41 employees as of Feb 5, 2024.

Goldfinch Bio - Classification

Industry
  • Hardware
Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medicines
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified